Geneva Advisors’s Theriva Biologics TOVX Stock Holding History

Geneva Advisors’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-2	Closed	-$31K	–	690
2015 Q3	$31K	Buy	+2	New	+$49.2K	﹤0.01%	606

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BGA

Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geneva Advisors's TOVX Position: Q4 2015 in Review

Geneva Advisors sold out of Theriva Biologics (TOVX) in Q4 2015, closing a stake of 2 shares — an estimated $31K sold.

Geneva Advisors first reported a position in TOVX in Q3 2015 and held it in 1 quarter. The position peaked at $31K in Q3 2015. 51 funds tracked by Wall St. Rank hold TOVX as of Q4 2015.

Geneva Advisors reported no remaining Theriva Biologics position as of Q4 2015 after selling out during the quarter.
Geneva Advisors sold 2 Theriva Biologics shares in Q4 2015, an estimated $31K.
Geneva Advisors first reported a position in Theriva Biologics in Q3 2015 and held it in 1 quarter.
Geneva Advisors's Theriva Biologics position peaked at $31K in Q3 2015.
51 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2015.

Based on Geneva Advisors's 13F filing for Q4 2015, filed 4 Feb 2016.